17653-94-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-methoxyphenyl)-2-methylpropanoic acid is used as an analgesic for relieving pain associated with various conditions such as arthritis, menstrual cramps, minor injuries, and headaches.
2-(3-methoxyphenyl)-2-methylpropanoic acid is used as an anti-inflammatory agent for reducing inflammation in conditions like arthritis and other inflammatory disorders.
2-(3-methoxyphenyl)-2-methylpropanoic acid is used as an antipyretic to reduce fever and lower body temperature.
2-(3-methoxyphenyl)-2-methylpropanoic acid is available over the counter in various forms, including tablets, capsules, and creams, for easy accessibility and self-medication.
It is important to consult a healthcare professional before using 2-(3-methoxyphenyl)-2-methylpropanoic acid, as it can have potential side effects and interactions with other medications.

Upstream product

• 74-83-9 methyl bromide 
• 3146-60-9 2-(3-methoxyphenyl)propanoic acid 
• 32454-33-4 methyl 2-(3-methoxyphenyl)-2-methylpropanoate 
• 728912-67-2 ethyl 2-(3-methoxyphenyl)-2-methyl-propanoate 
• 31469-25-7 1,1-bis(trimethylsiloxy)-2-methylprop-1-ene 
• 19924-43-7 3-methoxyphenylacetonitrile 
• 77-78-1 dimethyl sulfate 
• 25307-02-2 sodium 3-methoxyphenylacetate 
• 74-88-4 methyl iodide 
• 18927-05-4 methyl (3-methoxyphenyl)acetate 
• 17653-93-9 2-(3'-Methoxyphenyl)-2-methylpropionitrile 

Downstream Products

• 17653-95-1 2-(3-methoxyphenyl)-2-methyl-propan-1-ol 
• 1338222-69-7 C₁₅H₂₃NO₃ 
• 1620518-38-8 2-(3-hydroxyphenyl)-1-[5-(3-hydroxyphenyl)thiophen-2-yl]-2-methylpropan-1-one 
• 1620518-37-7 2-(3-methoxyphenyl)-1-[5-(3-methoxyphenyl)thiophen-2-yl]-2-methylpropan-1-one 
• 706792-50-9 [1-(3-methoxyphenyl)-1-methylethyl]carbamic acid benzyl ester 
• 717889-82-2 3-methoxyphenyl-dimethyl adamantyl acetamide 
• 72925-77-0 m-Methoxyneophyl methanesulfonate 
• 55841-52-6 3-(3-Methoxyphenyl)-3-methyl-butylamin 
• 17653-96-2 3-(m-methoxyphenyl)-3-methylbutyronitrile 
• 85620-02-6 1,2,3,4-tetrahydro-5,6,7-trimethoxy-1-(3'-methoxy-α,α-dimethylbenzyl)isoquinoline 
• 85620-03-7 1,2,3,4-tetrahydro-5,6,7-trimethoxy-1-(3'-methoxy-α,α-dimethylbenzyl)-2-methylisoquinoline 
• 85620-00-4 m-methoxy-α-methyl-N-(2,3,4-trimethoxyphenethyl)hydratropamide 
• 85620-01-5 3,4-dihydro-5,6,7-trimethoxy-1-(3'-methoxy-α,α-dimethylbenzyl)isoquinoline 
• 184906-32-9 3,3-Dimethyl-5-(1-phenyl-1H-tetrazol-5-yloxy)-2,3dihydroisoindol-1-one 

Relevant academic research and scientific papers

Unexpected formation of 3,3a,4,7a-tetrahydrobenzofuran-2,5-dione as well as arene carboxylic acids upon formal double exo nucleophilic addition of R1R2C-COO- to anisolechromium tricarbonyl complexes

Bis(trimethylsily)ketene acetals of the general structure 2 (R1 = H,Me,R2 = Me,Et,Pr(i),CMe = CH2) react at -78°C in the presence of Bu(t)OK with a series of arenechromium tricarbonyl complexes 3 to give as expected, after oxidation with I2 followed by silica gel chromatography, arylcarboxylic acids 7. In the case of anisolechromium tricarbonyl 8, besides the m-methoxyarylcarboxylic acids, tetrahydrobenzofuran-2,5-diones 11, are formed as the result of a double nucleophilic addition.

Palladium-Catalyzed Distal m-C-H Functionalization of Arylacetic Acid Derivatives

Herein, we present m-C-H olefination on derivatives of phenylacetic acids by tethering with a simple nitrile-based template through palladium catalysis. Notably, the versatility of the method is evaluated with a wide range of phenylacetic acid derivatives for obtaining the meta-olefination products in fair to excellent yields with outstanding selectivities under mild conditions. Significantly, the present strategy is successfully exemplified for the synthesis of drugs/natural product analogues (naproxen, ibuprofen, paracetamol, and cholesterol).

Cobalt-catalyzed C[sbnd]H activation/C[sbnd]O formation: Synthesis of benzofuranones

Herein, C[sbnd]H activation/C[sbnd]O formation reaction using novel cobalt catalytic system is reported. This reaction was given benzofuranones in moderate to excellent yields at room-temperature under air reaction conditions. The introduced strategy is efficient and low-cost method to synthesized benzofuranones from α,α-disubstitution acetic acid.

Palladium(II)-Catalyzed C(sp2)-H Carbonylation of Sterically Hindered Amines with Carbon Monoxide

A palladium-catalyzed, amine-directed C(sp2)-H carbonylation of α,α-disubstituted benzylamine under 1 atm of CO for the facile synthesis of sterically hindered benzolactam has been developed. The key to success is the use of 2,2,6,6-tetramethyl-1-piperidinyloxy as the crucial sole oxidant. The synthetic utility of this transformation has been demonstrated by the first concise synthesis of the natural product spiropachysin-20-one.

Novel, potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors as potential therapeutics for osteoporosis with dual human and mouse activities

17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) is responsible for the oxidation of the highly active estradiol (E2) and testosterone (T) into the less potent estrone (E1) and Δ4-androstene-3,17-dione (Δ4-AD), respectively. As 17β-HSD2 is present in bones and as estradiol and testosterone are able to induce bone formation and repress bone resorption, inhibition of this enzyme could be a new promising approach for the treatment of osteoporosis. Herein, we describe the design, the synthesis and the biological evaluation of 24 new 17β-HSD2 inhibitors in the 5-substituted thiophene-2-carboxamide class. Structure-activity and structure-selectivity relationships have been explored by variation of the sulfur atom position in the central core, exchange of the thiophene by a thiazole, substitution of the amide group with a larger moiety, exchange of the N-methylamide group with bioisosteres like N-methylsulfonamide, N-methylthioamide and ketone, and substitutions at positions 2 and 3 of the thiophene core with alkyl and phenyl groups leading to 2,3,5-trisubstituted thiophene derivatives. The compounds were evaluated on human and mouse enzymes. From this study, a novel highly potent and selective compound in both human and mouse 17β-HSD2 enzymes was identified, compound 21 (IC 50(h17β-HSD2) = 235 nM, selectivity factor toward h17β-HSD1 = 95, IC50 (m17β-HSD2) = 54 nM). This new compound 21 could be used for an in vivo proof of principle to demonstrate the true therapeutic efficacy of 17β-HSD2 inhibitors in osteoporosis. New structural insights into the active sites of the human and mouse enzymes were gained.

NEW COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein A, B, X, R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and t

CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS

Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.

TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE

The present invention relates to novel hydroxyethylamine compounds having Asp2 (β-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated β- amyloid levels or β-amyloid deposits, particularly Alzheimer's disease.